Abstract
Dyslipidemia in chronic kidney disease increases cardiovascular risk and progression of renal impairment. The probability of death from cardiovascular complications is higher than on the consequences of the end-stage kidney failure.
Cardioprotective and renoprotective effect of statins and fibrates is not only a lipid-lowering effect, but also further affecting lipid to an unrelated action. Statins reduce cardiovascular risk at all stages of chronic kidney disease, slowing down the decline in renal function, but their impact on the reduction of albuminuria/ proteinuria is not unique.
Fibrates, which slow down the progression of diabetic nephropathy through reduction of albuminuria, cannot be used with severe chronic renal insufficiency or renal failure. Controlled studies and clinical practice demonstrated that monotherapy with statins and fibrates is effective and safe.
In the treatment of mixed hyperlipidemia by combination of statin with fibrate or cholesterol absorption inhibitor, it is necessary to monitor potential side effects, tolerance and treatment compliance.